Dexcom
15-day accurate glucose sensing, zero fingersticks
San Diego, CA, US
Dexcom is a publicly traded medical device company headquartered in San Diego, California, specializing in continuous glucose monitors. Its devices are integrated into chronic-condition management platforms.
How We Help
Problem Statement
Dexcom addresses the need for real-time glucose insights for individuals with diabetes by providing continuous glucose monitoring (CGM) systems that track glucose levels, trends, and alerts, enabling informed decisions about diet, exercise, and insulin for better diabetes management, reduced HbA1c, and increased time in range.
Core Technology
Continuous Glucose Monitoring (CGM) Systems
Key Differentiators
Real-time glucose insights without traditional fingerstick testing; Pioneer in continuous glucose monitoring; Latest and most accurate CGM system cleared in the U.S. (G7); First FDA-approved over-the-counter (OTC) CGM (Stelo)
Clinical Focus
Diabetes Management; Endocrinology
Company Info
- Business Model
- Hybrid
Categories
Technologies
Clinical & IP
Clinical Validation
FDA 510(k) clearance for G7 with 87.7% agreement ±20 mg/dL across 130-patient multicenter trial. Stelo first OTC iCGM approved (March 2024). G6 real-world data: 77% glucose improvement in critical care; reduced hospitalizations in T2D insulin users.
MedStartr Index Score
?What do you think of Dexcom?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.